Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 20/20 | 0.83 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.81 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921681 | 1.00 | GPR132 (0.83) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL5921717 | 0.90 | GPR132 (0.81) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL5921710 | 0.90 | GPR132 (0.81) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL5921750 | 0.90 | GPR132 (0.78) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL5921751 | 0.90 | GPR132 (0.78) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL5921755 | 0.90 | GPR132 (0.78) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL5921658 | 0.84 | GPR132 (0.69) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL5921749 | 0.84 | PTPN1 (0.70) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL5921654 | 0.84 | GPR132 (0.69) | GPR132CMKLR2CMKLR1 | |
| SCHEMBL5921801 | 0.84 | GPR132 (0.69) | GPR132CMKLR2CMKLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166989-A1 | 2-naphthamide derivatives | BAYER HEALTHCARE AG (DE) | 2006-07-27 | — | — | US | claimed |
| EP-1515941-A1 | 2-NAPHTHAMIDE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | claimed |
| WO-2003106402-A1 | 2-NAPHTAMIDE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-24 | — | — | WO | claimed |
| US-20060166989-A1 | 2-naphthamide derivatives | BAYER HEALTHCARE AG (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1515941-A1 | 2-NAPHTHAMIDE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003106402-A1 | 2-NAPHTAMIDE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166989-A1 | 2-naphthamide derivatives | BPHL, F2RL1, HRH2 | GPR132 1025/4885CMKLR2 110/4885CMKLR1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.